We’ve recently updated our valuation analysis.

Imugene Valuation

Is IMU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMU?

Other financial metrics that can be useful for relative valuation.

IMU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue66.6x
Enterprise Value/EBITDA-24.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does IMU's PB Ratio compare to its peers?

The above table shows the PB ratio for IMU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average10.7x
CUV Clinuvel Pharmaceuticals
10.9x30.4%AU$1.4b
AVH AVITA Medical
2.4x32.0%AU$294.9m
RAC Race Oncology
8.9xn/aAU$320.0m
TLX Telix Pharmaceuticals
20.6x89.7%AU$2.2b
IMU Imugene
6.9x1.2%AU$963.3m

Price-To-Book vs Peers: IMU is good value based on its Price-To-Book Ratio (6.9x) compared to the peer average (10.7x).


Price to Earnings Ratio vs Industry

How does IMU's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a

Price-To-Book vs Industry: IMU is expensive based on its Price-To-Book Ratio (6.9x) compared to the Australian Biotechs industry average (3.2x)


Price to Book Ratio vs Fair Ratio

What is IMU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMU's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IMU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.15
AU$0.51
+237.8%
29.7%AU$0.71AU$0.35n/a3
Jan ’24AU$0.14
AU$0.51
+249.4%
29.7%AU$0.71AU$0.35n/a3
Dec ’23AU$0.19
AU$0.51
+166.7%
29.7%AU$0.71AU$0.35n/a3
Nov ’23AU$0.20
AU$0.52
+165.0%
28.1%AU$0.71AU$0.36n/a3
Oct ’23AU$0.18
AU$0.52
+187.0%
28.1%AU$0.71AU$0.36n/a3
Sep ’23AU$0.25
AU$0.58
+132.0%
22.4%AU$0.71AU$0.45n/a2
Aug ’23AU$0.23
AU$0.58
+157.8%
22.4%AU$0.71AU$0.45n/a2
Jul ’23AU$0.20
AU$0.58
+197.4%
22.4%AU$0.71AU$0.45n/a2
Jun ’23AU$0.18
AU$0.58
+222.2%
22.4%AU$0.71AU$0.45n/a2
May ’23AU$0.22
AU$0.55
+151.5%
20.4%AU$0.71AU$0.45n/a3
Apr ’23AU$0.25
AU$0.55
+121.3%
20.4%AU$0.71AU$0.45n/a3
Mar ’23AU$0.27
AU$0.58
+117.6%
16.4%AU$0.71AU$0.50n/a3
Feb ’23AU$0.33
AU$0.58
+74.7%
16.4%AU$0.71AU$0.50n/a3
Jan ’23AU$0.40
AU$0.61
+53.8%
15.4%AU$0.71AU$0.52AU$0.142
Dec ’22AU$0.51
AU$0.61
+21.8%
15.4%AU$0.71AU$0.52AU$0.192
Nov ’22AU$0.52
AU$0.57
+10.7%
8.8%AU$0.62AU$0.52AU$0.202
Oct ’22AU$0.47
AU$0.47
0.0%
9.5%AU$0.52AU$0.43AU$0.182
Sep ’22AU$0.40
AU$0.34
-15.0%
26.5%AU$0.43AU$0.25AU$0.252
Aug ’22AU$0.29
AU$0.34
+15.3%
26.5%AU$0.43AU$0.25AU$0.232
Jul ’22AU$0.35
AU$0.34
-2.9%
26.5%AU$0.43AU$0.25AU$0.202
Jun ’22AU$0.38
AU$0.34
-9.3%
26.5%AU$0.43AU$0.25AU$0.182
May ’22AU$0.19
AU$0.20
+5.3%
0%AU$0.20AU$0.20AU$0.221
Apr ’22AU$0.12
AU$0.20
+66.7%
0%AU$0.20AU$0.20AU$0.251
Mar ’22AU$0.10
AU$0.20
+100.0%
0%AU$0.20AU$0.20AU$0.271
Feb ’22AU$0.10
AU$0.20
+100.0%
0%AU$0.20AU$0.20AU$0.331
Jan ’22AU$0.10
AU$0.20
+100.0%
0%AU$0.20AU$0.20AU$0.401

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies